DermaTend Firm Faces Re-Labeling To Keep Lotions On Market
This article was originally published in The Rose Sheet
Executive Summary
Solace International’s recall announcement notes that “DermaTend is not FDA-approved,” and “using these DermaTend products instead of seeking medical attention could result in delayed diagnosis of conditions such as cancer.”
You may also be interested in...
In Brief
NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.